Medication info

Stavaster Tablet 5 mg (Rosuvastatin Calcium)

Prescription medicationApproval withdrawn
Ingredient · strength
Rosuvastatin Calcium›Strength being verified
Manufacturer / importer
SANDOZ KOREA
Appearance
Brown round film-coated tablets
Packaging
28 tablets/Alu-Alu (7 tablets/Alu-Alu x 4)
Approval status
Approval withdrawn

MFDS item code 201404477 · Approved 2014.09.30

This product's status changed to Approval withdrawn on 2023.06.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goals, and patient response, and may be increased up to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on administration of doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Importer
SANDOZ KOREA

Efficacy & effects

Improvement of dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • early coronary heart disease family history
View approved original text

This medication is used to assist dietary management when diet and exercise alone are not sufficient for patients with primary hypercholesterolemia and mixed hyperlipidemia. It is also used as an adjunct in the treatment of patients with homozygous familial hypercholesterolemia. It has the effect of lowering total cholesterol and LDL-cholesterol levels, thereby delaying the progression of atherosclerosis. It can also be used as an adjunct to dietary therapy for pediatric patients aged 10 to 17 years who meet strict conditions, and it aids in the dietary management of primary dysbetalipoproteinemia. Additionally, it contributes to the reduction of the risk of stroke, myocardial infarction, and arterial revascularization in men over 50 years and women over 60 years who have cardiovascular risk factors. This medication effectively improves the risk of hyperlipidemia and cardiovascular disease.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goals, and patient response, and may be increased up to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on administration of doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For example, patients allergic to the components of this medication, those with liver dysfunction, muscle disorders, and patients on specific medications should not use this drug. Pregnant or breastfeeding women, as well as women of childbearing potential not practicing adequate contraception, should also avoid taking this medication, and it should only be given to women capable of becoming pregnant after fully explaining the high likelihood of not getting pregnant and the risks to the fetus. Additionally, patients vulnerable to muscle disorders should avoid high doses of this medication, and caution is required in patients with impaired renal function or hypothyroidism. Patients with a history of significant alcohol intake or liver disease should have their liver function tested regularly when taking this medication, and if symptoms like muscle pain or weakness occur, they should notify their healthcare provider immediately. If severe muscle pain occurs after exercise or if muscle-related levels are abnormally high in blood tests, discontinuation of this medication may be considered. This medication contains lactose, so patients with lactose intolerance should not take it. When taken with specific other medications, the drug concentration may increase, raising the risk of side effects; therefore, patients should consult their healthcare provider if they are taking other medications. During pregnancy and breastfeeding, safety has not been established, and use should be avoided, with women of childbearing potential required to use appropriate contraceptive methods. In the case of overdose, no specific antidote exists, so treatment should be based on symptoms while monitoring liver function and muscle levels. This medication does not appear to significantly affect driving or operating machinery, but caution is necessary as dizziness may occur. Finally, if severe skin reactions or signs of serious liver damage occur during treatment with this medication, it should be discontinued immediately, and consultation with a healthcare provider is necessary.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminase levels, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, dysesthesia, chest discomfort, loss of appetite, abdominal bloating, abnormal liver function tests, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to keep the storage temperature between 1°C and 30°C room temperature. This will help maintain the medication's efficacy over time.

Appearance and packaging

Appearance

Brown round film-coated tablets

Package unit

28 tablets/Alu-Alu (7 tablets/Alu-Alu x 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.